William Lambert

William Lambert, Ph.D., is the founder of Module 3 Pharmaceutical Consulting where he provides expert consultation in the Chemistry, Manufacturing, and Controls area for both large and small molecule therapeutics. Prior to Module 3, he was the Vice President of CMC at Omeros Corporation. At AstraZeneca/MedImmune, he led the Innovative Drug Delivery Group. He was Sr. VP of Pharmaceutical Development at Pacira Pharmaceuticals. He also held various positions in drug delivery, product development, and manufacture at Eisai Inc., Pfizer, and the Upjohn Company. In the above positions, he contributed to the development and registration efforts of several marketed drugs including Corvert (anti-arrhythmic), Trovan (antibiotic), Halaven (anti-cancer), Exparel (post-surgical pain), Fasenra (benralizumab, asthma), and Omidria (ophthalmic).

Dr. Lambert received his B.S. in Pharmacy from the Univ. of Rhode Island followed by graduate studies in Pharmaceutics at the Univ. of Michigan and Utah. He is a member of the Advisory Boards of J. Pharm. Sci. and the Handbook of Pharmaceutical Excipients, and was previously on boards for the USP Excipient Expert Committee, AFPE, NIPTE, and chair of the Pharm Tech Section of the AAPS.